Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry PerspectiveHardik Mody, Vijay Upreti, Swati Gupta et al.|Clinical Pharmacology & Therapeutics|2023Cited by 26
Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug DevelopmentJochem Gokemeijer, Sofie Pattijn, Theresa J. Goletz et al.|The AAPS Journal|2023Cited by 22
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR‐T and TCR‐T Cellular Therapies DevelopmentJochem Gokemeijer, Vibha Jawa, Nanda Balasubramanian et al.|Clinical Pharmacology & Therapeutics|2023Cited by 9
Immunogenicity Risk Assessment of Process-Related Impurities in An Engineered T Cell Receptor Cellular ProductJohanna Mora, Chloé Ackaert, Daron Forman et al.|Journal of Pharmaceutical Sciences|2024Cited by 3